Eph Receptor Tyrosine Kinases in Tumor Immunity

Overview

Journal Cancer Res

Specialty Oncology

Date 2016 Nov 5

PMID 27811149

Citations 41

Authors

Eileen Shiuan

Jin Chen

Affiliations

Soon will be listed here.

Abstract

The family of Eph receptor tyrosine kinases and their ephrin ligands regulate a diverse array of physiologic processes, such as axonal guidance, bone remodeling, and immune cell development and trafficking. Eph/ephrin interactions have also been implicated in various pathologic processes, including inflammation, cancer, and tumor angiogenesis. Because Eph receptors play prominent roles in both the immune system and cancer, they likely impact the tumor immune microenvironment, an area in which Eph receptors remain understudied. Here, we provide the first comprehensive review of Eph receptors in the context of tumor immunity. With the recent rise of cancer immunotherapies as promising therapeutic interventions, further elucidation of the roles of Eph receptors in the tumor immune microenvironment will be critical for understanding and developing novel targets against tumor immune evasion. Cancer Res; 76(22); 6452-7. ©2016 AACR.

Citing Articles

Establishing a prognostic model with immune-related genes and investigating EPHB6 expression pattern in breast cancer.

Lyu H, Zhou T, Sun X, Chen H, Li J, Shao M Sci Rep. 2025; 15(1):6630.

PMID: 39994456 PMC: 11850720. DOI: 10.1038/s41598-025-91318-z.

Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node.

Xia Y, Huang Y, Liu Z, Song S, Wang Y, Luo J Front Immunol. 2025; 16:1548102.

PMID: 39925800 PMC: 11802514. DOI: 10.3389/fimmu.2025.1548102.

A pan-cancer analysis of EphA family gene expression and its association with prognosis, tumor microenvironment, and therapeutic targets.

Cui Z, Liu C, Wang X, Xiang Y Front Oncol. 2024; 14:1378087.

PMID: 38952552 PMC: 11215048. DOI: 10.3389/fonc.2024.1378087.

Diversity of Intercellular Communication Modes: A Cancer Biology Perspective.

Ebrahim T, Ebrahim A, Kandouz M Cells. 2024; 13(6.

PMID: 38534339 PMC: 10969453. DOI: 10.3390/cells13060495.

Cell Death, by Any Other Name….

Kandouz M Cells. 2024; 13(4.

PMID: 38391938 PMC: 10886887. DOI: 10.3390/cells13040325.

References

Okada H, Butterfield L, Hamilton R, Hoji A, Sakaki M, Ahn B . Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2014; 21(2):286-94. PMC: 4297523. DOI: 10.1158/1078-0432.CCR-14-1790. View

Kania A, Klein R . Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol. 2016; 17(4):240-56. DOI: 10.1038/nrm.2015.16. View

Hatano M, Kuwashima N, Tatsumi T, Dusak J, Nishimura F, Reilly K . Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med. 2004; 2(1):40. PMC: 535538. DOI: 10.1186/1479-5876-2-40. View

Korff T, Braun J, Pfaff D, Augustin H, Hecker M . Role of ephrinB2 expression in endothelial cells during arteriogenesis: impact on smooth muscle cell migration and monocyte recruitment. Blood. 2008; 112(1):73-81. DOI: 10.1182/blood-2007-12-128835. View

Okazaki T, Ni A, Baluk P, Ayeni O, Kearley J, Coyle A . Capillary defects and exaggerated inflammatory response in the airways of EphA2-deficient mice. Am J Pathol. 2009; 174(6):2388-99. PMC: 2684202. DOI: 10.2353/ajpath.2009.080949. View

Choi Y, Syeda F, Walker J, Finerty Jr P, Cuerrier D, Wojciechowski A . Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009; 19(15):4467-70. PMC: 2730633. DOI: 10.1016/j.bmcl.2009.05.029. View

Luo H, Yu G, Wu Y, Wu J . EphB6 crosslinking results in costimulation of T cells. J Clin Invest. 2002; 110(8):1141-50. PMC: 150798. DOI: 10.1172/JCI15883. View

Yamaguchi S, Tatsumi T, Takehara T, Sasakawa A, Hikita H, Kohga K . Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity. Cancer Immunol Immunother. 2008; 57(12):1861-9. PMC: 11029894. DOI: 10.1007/s00262-008-0514-5. View

Tatsumi T, Herrem C, Olson W, Finke J, Bukowski R, Kinch M . Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003; 63(15):4481-9. View

10.

Wu J, Luo H . Recent advances on T-cell regulation by receptor tyrosine kinases. Curr Opin Hematol. 2005; 12(4):292-7. DOI: 10.1097/01.moh.0000166497.26397.9f. View

11.

Arvanitis D, Davy A . Eph/ephrin signaling: networks. Genes Dev. 2008; 22(4):416-29. PMC: 2731651. DOI: 10.1101/gad.1630408. View

12.

Zhang J, Eguchi J, Kruse C, Gomez G, Fakhrai H, Schroter S . Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007; 13(2 Pt 1):566-575. PMC: 4030524. DOI: 10.1158/1078-0432.CCR-06-1576. View

13.

Li M, Wang B, Wu Z, Shi X, Zhang J, Han S . Treatment of Dutch rat models of glioma using EphrinA1-PE38/GM-CSF chitosan nanoparticles by in situ activation of dendritic cells. Tumour Biol. 2015; 36(10):7961-6. DOI: 10.1007/s13277-015-3486-z. View

14.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

15.

Yu G, Luo H, Wu Y, Wu J . Mouse ephrinB3 augments T-cell signaling and responses to T-cell receptor ligation. J Biol Chem. 2003; 278(47):47209-16. DOI: 10.1074/jbc.M306659200. View

16.

Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak J, Kinch M . EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 2005; 7(8):717-22. PMC: 1501889. DOI: 10.1593/neo.05277. View

17.

Pollack I, Jakacki R, Butterfield L, Hamilton R, Panigrahy A, Normolle D . Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 2016; 18(8):1157-68. PMC: 4933485. DOI: 10.1093/neuonc/now026. View

18.

Brantley-Sieders D, Zhuang G, Hicks D, Fang W, Hwang Y, Cates J . The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2007; 118(1):64-78. PMC: 2129239. DOI: 10.1172/JCI33154. View

19.

Amato K, Wang S, Hastings A, Youngblood V, Santapuram P, Chen H . Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J Clin Invest. 2014; 124(5):2037-49. PMC: 4001547. DOI: 10.1172/JCI72522. View

20.

Chen J, Song W, Amato K . Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev. 2014; 26(1):1-6. PMC: 4234705. DOI: 10.1016/j.cytogfr.2014.05.001. View